PF-06463922
98%
- Product Code: 124789
CAS:
1454846-35-5
| Molecular Weight: | 406.41 g./mol | Molecular Formula: | C₂₁H₁₉FN₆O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
PF-06463922 is primarily utilized in the field of oncology as a targeted therapy for the treatment of various cancers. It functions as an ALK (anaplastic lymphoma kinase) inhibitor, making it particularly effective against non-small cell lung cancer (NSCLC) that is driven by ALK mutations. The compound is designed to penetrate the blood-brain barrier, which enhances its efficacy in treating brain metastases, a common complication in ALK-positive NSCLC patients. Its application extends to clinical trials where it is being evaluated for its potential to improve patient outcomes by reducing tumor growth and increasing progression-free survival. Additionally, PF-06463922 is being studied for its role in overcoming resistance to earlier generations of ALK inhibitors, offering a promising option for patients who have developed resistance to initial treatments.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $38.93 |
+
-
|
| 0.025 | 10-20 days | $123.52 |
+
-
|
| 0.100 | 10-20 days | $360.66 |
+
-
|
PF-06463922
PF-06463922 is primarily utilized in the field of oncology as a targeted therapy for the treatment of various cancers. It functions as an ALK (anaplastic lymphoma kinase) inhibitor, making it particularly effective against non-small cell lung cancer (NSCLC) that is driven by ALK mutations. The compound is designed to penetrate the blood-brain barrier, which enhances its efficacy in treating brain metastases, a common complication in ALK-positive NSCLC patients. Its application extends to clinical trials where it is being evaluated for its potential to improve patient outcomes by reducing tumor growth and increasing progression-free survival. Additionally, PF-06463922 is being studied for its role in overcoming resistance to earlier generations of ALK inhibitors, offering a promising option for patients who have developed resistance to initial treatments.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :